Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACOROTCMKTS:ENZNNASDAQ:IDRANASDAQ:MBOT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$0.66-24.9%$11.42$0.61▼$24.20$820K1.4119,299 shs416,900 shsENZNEnzon Pharmaceuticals$0.07$0.08$0.06▼$0.23N/A0.336,329 shsN/AIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsMBOTMicrobot Medical$0.87-1.8%$1.18$0.86▼$4.37$12.55M1.64123,295 shs49,474 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%-94.54%-96.06%-93.26%ENZNEnzon Pharmaceuticals0.00%-3.26%+3.37%-18.31%-66.34%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MBOTMicrobot Medical+2.60%-13.83%-25.42%-31.20%-45.88%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMBOTMicrobot Medical1.7356 of 5 stars3.53.00.00.02.90.80.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AMBOTMicrobot Medical3.00Buy$7.00703.31% UpsideCurrent Analyst RatingsLatest IDRA, ENZN, ACOR, and MBOT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.01$33.05 per share0.02($127.17) per share-0.01ENZNEnzon Pharmaceuticals$30KN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/AMBOTMicrobot MedicalN/AN/AN/AN/A$0.38 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/A∞N/A-214.95%-2,206.93%-83.28%5/9/2024 (Estimated)ENZNEnzon Pharmaceuticals$1.37M$0.017.24∞N/AN/A46.47%2.92%N/AIDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/AMBOTMicrobot Medical-$10.74M-$1.08N/A∞N/AN/A-164.13%-125.22%5/15/2024 (Estimated)Latest IDRA, ENZN, ACOR, and MBOT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023MBOTMicrobot Medical-$0.25-$0.26-$0.01-$0.26N/AN/A3/20/2024Q4 2023ENZNEnzon PharmaceuticalsN/A$0.01+$0.01$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26ENZNEnzon PharmaceuticalsN/A27.6227.62IDRAIdera PharmaceuticalsN/A1.561.56MBOTMicrobot MedicalN/A2.092.09OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%ENZNEnzon PharmaceuticalsN/AIDRAIdera Pharmaceuticals12.18%MBOTMicrobot Medical16.30%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%ENZNEnzon Pharmaceuticals0.27%IDRAIdera Pharmaceuticals5.05%MBOTMicrobot Medical10.64%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataENZNEnzon PharmaceuticalsN/AN/AN/ANot OptionableIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableMBOTMicrobot Medical2114.40 million12.87 millionOptionableIDRA, ENZN, ACOR, and MBOT HeadlinesSourceHeadlineMicrobot Medical (MBOT) Price Target Decreased by 12.50% to 7.14msn.com - April 18 at 7:13 AMAnalysts Offer Predictions for Microbot Medical Inc.'s Q1 2024 Earnings (NASDAQ:MBOT)americanbankingnews.com - April 18 at 5:46 AMMicrobot Medical (NASDAQ:MBOT) Price Target Cut to $7.00 by Analysts at HC Wainwrightamericanbankingnews.com - April 17 at 3:48 AMAnalysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)markets.businessinsider.com - April 16 at 5:45 PMMicrobot Medical Shares Status Following Recent Geopolitical Eventsglobenewswire.com - April 15 at 8:30 AM3 AI Stocks Wall Street Expects to Return Up to 595% in 2024msn.com - March 28 at 10:05 AMMBOT Stock Earnings: Microbot Medical Misses EPS for Q4 2023investorplace.com - March 27 at 11:03 PMMBOT Apr 2024 3.000 callca.finance.yahoo.com - March 16 at 10:15 AMMicrobot Medical Stock (NASDAQ:MBOT) Dividends: History, Yield and Datesbenzinga.com - February 26 at 1:07 AMMBOT Jul 2024 2.500 putfinance.yahoo.com - February 21 at 2:27 AMMBOT Apr 2024 5.000 callfinance.yahoo.com - February 21 at 2:27 AMMBOT Mar 2024 2.500 callfinance.yahoo.com - February 18 at 3:16 PMMicrobot Medical Inc.: Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the USfinanznachrichten.de - February 5 at 12:27 PMMicrobot Medical submits surgical robot for FDA IDEmassdevice.com - February 5 at 12:27 PMMicrobot files FDA application for clinical study of Liberty systemmsn.com - February 5 at 12:27 PMMicrobot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the USfinance.yahoo.com - February 5 at 12:27 PMLooking Into Microbot Medical's Recent Short Interestbenzinga.com - February 2 at 1:43 PMMicrobot Medical Settles: Regulation FD Disclosure Updatemsn.com - January 31 at 6:41 PMMicrobot Medical Inc.: Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Mattersfinanznachrichten.de - January 30 at 4:59 PMMicrobot Medical announces settlement resolving legal mattersmsn.com - January 30 at 9:28 AMMicrobot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Mattersfinance.yahoo.com - January 30 at 9:28 AMMicrobot Medical expands U.S. operations to prep for first in-human clinical studytherobotreport.com - January 24 at 12:41 PMMicrobot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Studyfinance.yahoo.com - January 18 at 10:30 AMMicrobot Medical Shares Drop 20% After Exercising Investment Optionsmarketwatch.com - December 29 at 4:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Enzon PharmaceuticalsOTCMKTS:ENZNEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.Idera PharmaceuticalsNASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.Microbot MedicalNASDAQ:MBOTMicrobot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. In addition, it provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.